Notch pathway inhibition with LY3039478 in soft tissue sarcoma and gastrointestinal stromal tumours.

导出 LinkOut

翻译打印收藏纠错

作者： Olivier,Mir ^[1] ; Analia,Azaro ^[2] ; Jaime,Merchan ^[3] ; Rashmi,Chugh ^[4] ; Jonathan,Trent ^[3] ; Jordi,Rodon ^[5] ; Ute,Ohnmacht ^[6] ; J T,Diener ^[6] ; Claire,Smith ^[7] ; Eunice,Yuen ^[7] ; Gerard Joseph,Oakley ^[6] ; Axel,Le Cesne ^[1] ; Jean-Charles,Soria ^[1] ; Karim A,Benhadji ^[6] ; Christophe,Massard ^[8]

作者单位： Institut Gustave Roussy Cancer Campus, Drug Development Department, Villejuif Cedex, France. ^[1] Molecular Therapeutics Research Unit, Department of Medical Oncology, Vall D'Hebron University Hospital, and Pharmacology Department, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain. ^[2] University of Miami, Sylvester Comprehensive Cancer Center, United States. ^[3] University of Michigan, United States. ^[4] MD Anderson Cancer Center, United States. ^[5] Eli Lilly and Company, United States. ^[6] Eli Lilly and Company, United Kingdom. ^[7] Institut Gustave Roussy Cancer Campus, Drug Development Department, Villejuif Cedex, France. Electronic address: christophe.massard@gustaveroussy.fr. ^[8]

关键词 Angiosarcoma Gastrointestinal stromal tumours Leiomyosarcoma Liposarcoma Notch inhibitor Pleomorphic sarcoma Rhabdomyosarcoma Soft tissue sarcoma